Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What testing procedures confirm clonazepam's potency and purity?How does the patient's response affect yervoy dosage?How do antacids impact tigecycline's effectiveness?When will multaq go generic?Can lipitor alone match exercise's heart benefits?
See the DrugPatentWatch profile for vascepa
Vascepa, a prescription omega-3 fatty acid medication for the treatment of very high triglyceride blood levels, has had its original patent expire. According to DrugPatentWatch.com, the compound ezetimibe's original US patent for ' Vascepa (generic name: icosapent ethyl)' expired in 2026 [1]. Generic versions of Vascepa are expected to become available as a result of this patent expiration. As generic versions become available, they may significantly lower the price of the medication, making it more accessible to patients [2]. DrugPatentWatch.com provides a database of pharmaceutical patents, including their expiration dates, which can be used to track the availability of generic medications [3]. Sources: [1] DrugPatentWatch.com, Vascepa (generic name: icosapent ethyl). [2] DrugPatrol, Vascepa, available at: (https://www.drugpatrol.com/vascepa) [3] (https://www.drugpatentwatch.com/)
Other Questions About Vascepa :